Receptor nicotínico, galantamina y enfermedad de Alzheimer

Arroyo, Gómez-Martino; Aldea, Marta; Fuentealba, Jorge; Garcı́a, Antonio G.

doi:10.33588/rn.3411.2002316

RevNeurol

2002

DOI: 10.33588/rn.3411.2002316

|View full text |Cite

Receptor nicotínico, galantamina y enfermedad de Alzheimer

Gómez-Martino Arroyo

Marta Aldea²,

Jorge Fuentealba³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2004

2014

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer’s Disease

Xia

Cheng

et al. 2014

Mol Neurobiol

View full text Add to dashboard Cite

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, which causes the deterioration of memory and other cognitive abilities of the elderly. Previous lines of research have shown that Aβ is an essential factor in AD pathology and the soluble oligomeric species of Aβ peptide is presumed to be the drivers of synaptic impairment in AD. However, the exact mechanisms underlying Aβ-induced synapse dysfunction are still not fully understood. Recently, increasing evidence suggests that some potential receptors which bind specifically with Aβ may play important roles in inducing the toxicity of the neurons in AD pathology. These receptors include the cellular prion protein (PrPc), the α7 nicotinic acetylcholine receptor (α7nAChR), the p75 neurotrophin receptor (p75(NTR)), the beta-adrenergic receptors (β-ARs), the Eph receptors, the paired immunoglobulin-like receptor B (PirB), the PirB's human ortholog receptor (LilrB2), and the Fcγ receptor II-b (FcγRIIb). This review summarizes the characters of these prominent receptors and how the bindings of them with Aβ inhibit the LTP, decrease the number of dendritic spine, damage the neurons, and so on in AD pathogenesis. Blocking or rescuing these receptors may have significant importance for AD treatments.

show abstract

The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer’s Disease

Xia

Cheng

et al. 2014

Mol Neurobiol

View full text Add to dashboard Cite

show abstract

Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors

Roman¹,

Badı́a²,

Camps³

et al. 2005

Brain Research

View full text Add to dashboard Cite

Galantamine: use in Alzheimer’s disease and related disorders

Bullock¹

2004

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Galantamine (Reminyl) has long been used as a traditional medicine and has an interesting pharmacology as it is both a reversible acetylcholinesterase inhibitor and an allosteric potentiator of nicotinic cholinergic receptors. The efficacy of galantamine has been studied in an extensive development program in Alzheimer's disease, and mixed and vascular dementia. Randomized, double-blind, placebo-controlled trials of up to 6 months duration and subsequent open-label follow-up studies have produced a broad spectrum of beneficial effects on cognitive and noncognitive disease symptoms. Apparent benefits for caregivers paralleled these, with a potentially reduced burden and cost. It appears that early and continued treatment maximizes the observed effects, which translate into economic terms, when applied to cost-effectiveness models. Overall, galantamine has a broad ranging efficacy and tolerability across an increasing range of conditions.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Receptor nicotínico, galantamina y enfermedad de Alzheimer

Cited by 3 publications

References 0 publications

The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer’s Disease

The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer’s Disease

Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors

Galantamine: use in Alzheimer’s disease and related disorders

Contact Info

Product

Resources

About